News

InvestorsHub on MSN56m
Nektar Therapeutics Shares Surge 140% After Atopic Dermatitis Drug Meets Key Study Goals
Nektar Therapeutics (NASDAQ:NKTR) saw its stock soar 140% following promising Phase 2b trial results for its experimental treatment rezpegaldesleukin in moderate-to-severe atopic dermatitis. The ...
STAT48m
Vaccine developer raises $45M for influenza drug trial
Nektar Therapeutics said its embattled immune drug rezpeg significantly improved skin clearance rates in patients with atopic ...